ArticleImmunoTargets and therapy2026
RNA Sequencing Analyses and Validation of Immune-Related Genes in EBV-Specific Cytotoxic T Lymphocytes During Latent Infection.
Article in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epstein-Barr virus (EBV) infects more than 90% of the global population, but the immune mechanism underlying its infection remains incompletely understood. Methods: In this study, transcriptomic profiling and validation of differentially expressed genes (DEGs) were performed between Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) and nonspecific CTLs via RNA sequencing (RNA-seq). Bioinformatics analyses, including Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, functional molecular module construction, and key gene analysis, were conducted to explore the biological functions and potential regulatory mechanisms of the DEGs. Results: A total of 1236 DEGs were identified in the EBV-CTL group compared with the nonspecific CTL group, including 645 upregulated genes and 591 downregulated genes. GO enrichment analysis revealed that these DEGs were localized mainly to cell membranes and MHC class II protein complexes and were involved in biological processes such as cellular defense, leukocyte activation, proliferation, differentiation, and chemotaxis. KEGG pathway enrichment analysis revealed that the JNK/p38 MAPK pathway was the most significantly enriched signaling pathway, with key DEGs including Conclusion: Our transcriptomic analysis reveals the unique gene expression profile of EBV-CTLs and identifies the JNK/p38 MAPK pathway and hub genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.